Associated Papers
CRISPR/Cas9-Mediated Induction of Relapse-Specific NT5C2 and PRPS1 Mutations Confers Thiopurine Resistance as a Relapsed Lymphoid Leukemia Model.
Nguyen TTT et al.
Molecular Pharmacology, 2023
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
34630336 (PubMed )
Supplement: Table_1.xlsx › Tab2
Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Dieck CL et al.
Cancer Cell, 2018
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Tzoneva G et al.
Nature, 2018
Oligomeric interface modulation causes misregulation of purine 5´-nucleotidase in relapsed leukemia.
Hnízda A et al.
Bmc Biology, 2016
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Tzoneva G et al.
Nature Medicine, 2013
Therapeutic resistance: ALL-important mutations.
Seton-Rogers S
Nature Reviews. Cancer, 2013
Select a paper to view details